The future of probiotics for disorders of the brain-gut axis

Advances in Experimental Medicine and Biology

Volumn 817, Issue , 2014, Pages 417-432

  Quigley, Eamonn M M ^a   Shanahan, Fergus ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; RIFAXIMIN;

ABDOMINAL DISTENSION; ARTICLE; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM INFANTIS; BILE ACID METABOLISM; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DYSPEPSIA; FECES COMPOSITION; FERMENTATION; FLATULENCE; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; INTESTINE TRANSIT TIME; IRRITABLE COLON; LACTOBACILLUS; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SMALL INTESTINAL BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE; ANIMAL; BRAIN; INFLAMMATORY BOWEL DISEASE; INTESTINE; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; REVIEW;

ANIMALIA; BACTERIA (MICROORGANISMS);

ANIMALS; BRAIN; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MICROBIOTA; PROBIOTICS;

EID: 84909581895     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0897-4_19     Document Type: Article

References (96)

1. Quigley EMM (2008) Gastrointestinal features. In: Factor SA, Weiner WJ (eds) Parkinson's disease - diagnosis and clinical management, 2nd edn. Demos Medical Publishing, New York, pp 99-105
2. Hadjivassiliou M, Sanders DS, Grünewald RA, Woodroofe N, Boscolo S, Aeschlimann D (2010) Gluten sensitivity: from gut to brain. Lancet Neurol 9:318-330
3. Mayer EA (2011) Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 12:453-466
4. Drossman DA (2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130:1377-1390
5. Suzuki H, Moayyedi P (2013) Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 10:168-174
6. Khalif IL, Konovitch EA, Maximova ID, Quigley EMM (2005) Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 37:838-849
7. Choung RS, Locke GR 3rd (2011) Epidemiology of IBS. Gastroenterol Clin North Am 40:1- 10
8. Clarke G, Quigley EM, Cryan JF, Dinan TG (2009) Irritable bowel syndrome: towards biomarker identification. Trends Mol Med 15:478-489
9. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480-1491
10. Quigley EM (2013) Bugs on the brain; brain in the gut-seeking explanations for common gastrointestinal symptoms. Ir J Med Sci 182:1-6
11. Thabane M, Kottachchi DT, Marshall JK (2007) Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 26:535-544
12. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR (2010) A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 55:392- 397
13. Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, Ringel Y (2011) Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrheapredominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 301:G799- G807
14. Durbán A, Abellán JJ, Jiménez-Hernández N, Salgado P, Ponce M, Ponce J, Garrigues V, Latorre A, Moya A (2012) Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. Environ Microbiol Rep 4:242-247
15. Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD (2012) Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 24:31-39
16. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133:24-33
17. Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Mäkivuokko H, Kajander K, Palva A (2009) Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 9:95
18. Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141:1792-1801
19. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J (2011) Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141:1782-1791
20. Rigsbee L, Agans R, Shankar V, Kenche H, Khamis HJ, Michail S, Paliy O (2012) Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 107:1740-1751
21. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y (2012) Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24:521-530
22. Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, Sokol H, Coffin B, Sabaté JM (2012) Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24:513-520
23. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, Martin JC, Pickering G, Ardid D, Eschalier A, Dubray C, Flint HJ, Bernalier-Donadille A (2012) Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 35:828-838
24. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M (2012) An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61:997-1006
25. Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A, Spiller RC, de Vos WM (2013) Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut (Epub ahead of print)
26. Durbán A, Abellán JJ, Jiménez-Hernández N, Artacho A, Garrigues V, Ortiz V, Ponce J, Latorre A, Moya A (2013) Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol Ecol 86:581-589 (Epub 2013 Aug 23)
27. Pimentel M, Chow EJ, Lin HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3503-3506
28. Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebocontrolled study. Am J Gastroenterol 98:412-419
29. Quigley EMM (2007) A 51-year old with IBS. Test or treat for bacterial overgrowth? Clin Gastroenterol Hepatol 5:114-1143
30. Quigley EMM, Abu-Shanab A (2009) The diagnosis of small intestinal bacterial overgrowth: the challenges persist! Expert Rev Gastroenterol Hepatol 3:77-87
31. Ford AC, Spiegel BM, Talley NJ, Moayyedi P (2009) Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 7:1279-1286
32. Quigley EM, Stanton C, Murphy EF (2013) The gut microbiota and the liver pathophysiological and clinical implications. J Hepatol 58:1020-1027
33. Pimentel M, Lembo A, Chey WD, Zakko S et al (2011) TARGET Study Group Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364:22- 32
34. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein A, Brandt L, Quigley E (2010) The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 59:325-332
35. Quigley EM, Flourie B (2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19:166-172
36. McFarland LV, Dublin S (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14:2650-2661
37. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M (2008) Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 51:1775-1780
38. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS (2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104:1033- 1049
39. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P (2009) A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9:15
40. Hungin AP, Mulligan C, Pot B, Whorwell P, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Rubin G, Winchester C, de Wit N; European Society for Primary Care Gastroenterology (2013) Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide. Aliment Pharmacol Ther 38:864-886
41. Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ (2009) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29:104-114
42. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17:895-904
43. Ringel Y, Ringel-Kulka T, Maier D, Carroll I, Galanko JA, Leyer G, Palsson OS (2011) Clinical trial: probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders - a double-blind study. J Clin Gastroenterol 45:518-525
44. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17:687-696
45. Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP, Federico A, Chilovi F, Milandri GL, De Bona M, Cavenati S, Gullini S, Abbiati R, Garbagna N, Cerutti R, Grossi E (2008) Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol 42(Suppl 3 Pt 2):S218-S223
46. Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13:701-712
47. Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B, Mayer EA (2013) Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144:1394-1401
48. Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. October 2001. www. who.int/foodsafety/publications/fs_management/en/probiotics.pdf?ua=1. Accessed 12 May 2014
49. Rachmilewitz D, Kayatura K, Karmeli F et al (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126:520-528
50. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKagney C, De Simone C, Madsen K (2004) DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 126:1358-1373
51. Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G, Bienenstock J (2006) Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 55:191-196
52. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F (2003) Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52:975-980
53. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimel C, Doyle J, Jewell L, De Simone C (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580-591
54. Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ (2004) Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53:1602-1609
55. O'Mahony L, McCarthy J, Kelly P, Shanahan F, Quigley EM (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541-551
56. O'Mahony L, O'Callaghan L, McCarthy J, Shilling D, Scully P, Sibartie S, Kavanagh E, Kirwan WO, Redmond RP, Collins JK, Shanahan F (2006) Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol 290:G839-G845
57. Hamilton-Miller JM, Shah S, Winkler JT (1999) Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. Public Health Nutr 2:223-229
58. Coeuret V, Gueguen M, Vernoux JP (2004) Numbers and strains of lactobacilli in some probiotic products. Int J Food Microbiol 97:147-156
59. Szajewska H, Fordymacka A, Bardowski J, Gorecki RK, Mrukowicz JZ, Banaszkiewicz A (2004) Microbiological and genetic analysis of probiotic products licensed for medicinal purposes. Med Sci Monit 10:BR346-BR350
60. Drisko J, Bischoff B, Giles C, Adelson M, Rao RV, McCallum R (2005) Evaluation of five probiotic products for label claims by DNA extraction and polymerase chain reaction analysis. Dig Dis Sci 50:1113-1117
61. Theunissen J, Britz TJ, Torriani S, Witthuhn RC (2005) Identification of probiotic microorganisms in South African products using PCR-based DGGE analysis. Int J Food Microbiol 98:11-21
62. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF (2004) Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2, CD003048
63. D'Souza AL, Rajkumar CH, Cooke J et al (2002) Probiotics in prevention of antibiotic associated diarrhea: meta-analysis. BMJ 324:1361-1366
64. Szajewska H, Skorka A, Dylag M (2007) Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 25:257-264
65. de Vrese M, Marteau PR (2007) Probiotics and prebiotics: effects on diarrhea. J Nutr 137 (3 Suppl 2):803S-811S
66. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124:1202-1209
67. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53:108-114
68. Sheil B, Shanahan F, O'Mahony L (2007) Probiotic effects on inflammatory bowel disease. J Nutr 137(3 Suppl 2):819S-824S
69. Quigley EMM (2007) Probiotics in the management of colonic disorders. Curr Gastroenterol Rep 9:434-440
70. Quigley EMM (2012) Probiotics in the management of functional bowel disorders promise fulfilled? Gastroenterol Clin North Am 41:805-819
71. Whorwell PJ, Altinger L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan B, Quigley EM (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101:326-333
72. Claesson MJ, Li Y, Leahy S, Canchaya C, van Pijkeren JP, Cerdeno-Tarraga AM, Parkhill J, Flynn S, O'Sullivan GC, Collins JK, Higgins D, Shanahan F, Fitzgerald GF, van Sinderen D, O'Toole PW (2006) Multireplicon genome architecture of Lactobacillus salivarius. Proc Natl Acad Sci U S A 103:6718-6723
73. Verdu EF, Bercik P, Bergonzelli GE, Huang XX, Blenerhasset P, Rochat F, Fiaux M, Mansourian R, Corthesy-Theulaz I, Collins SM (2004) Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 127:826-837
74. Verdu EF, Bercik P, Verma-Gandhu M, Huang X-X, Blenerhasset P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM (2006) Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55:182-190
75. Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L, Theodorou V (2006) Lactobacillus farciminis treatment suppresses stress-induced visceral hypersensitivity: a possible action through interaction with epithelial cells cytoskeleton contraction. Gut 55:1090- 1094
76. Rea MC, Clayton E, O'Connor PM, Shanahan F, Kiely B, Ross RP, Hill C (2007) Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol 56 (Pt 7):940-946
77. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG (2007) Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 104:7617-7621
78. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L (2004) Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127:502-513
79. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4:754-759
80. Frossard CP, Steidler L, Eigenmann PA (2007) Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 119:952-959
81. Gibson GR, Brummer RJ, Isolauri E, Lochs H, Morelli L, Ockhuizen T, Rowland IR, Schrezenmeir J, Stanton C, Verbeke K (2011) The design of probiotic studies to substantiate health claims. Gut Microbes 2:299-305
82. Binnendijk KH, Rijkers GT (2013) What is a health benefit? An evaluation of EFSA opinions on health benefits with reference to probiotics. Benef Microbes 4:223-230
83. Konieczna P, Groeger D, Ziegler M, Frei R, Ferstl R, Shanahan F, Quigley EMM, Kiely B, Akdis CA, O'Mahony L (2012) Bifidobacterium infantis 35624 administration induces Foxp3 + 1T regulatory cells in human peripheral blood - potential role for myeloid and plasmacytoid dendritic cells. Gut 61:354-366
84. Groeger D, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM (2013) Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 4:325-339
85. Li Z, Yang S, Lin H et al (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:343-350
86. Abu-Shanab A, Quigley EM (2010) The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7:691-701
87. Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ, Kiely B, Collins JK, Shanahan F (2004) Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 53:694-700
88. Osborn D, Sinn J (2007) Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev 4, CD006475
89. Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH (2006) Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta 1761:736- 744
90. Cryan JF, O'Mahony SM (2011) The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 23:187-192
91. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF (2011) Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 108:16050-16055
92. Desbonnet L, Clarke G, Shanahan F, Dinan TG, Cryan JF (2014) Microbiota is essential for social development in the mouse. Mol Psychiatry 19:146-148 (Epub 2013 May 21)
93. Dinan TG (2009) Inflammatory markers in depression. Curr Opin Psychiatry 22:32-36
94. Dennison U, McKernan D, Cryan J, Dinan T (2012) Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychol Med 42:1865-1871
95. Shanahan F, Dinan TG, Ross P, Hill C (2012) Probiotics in transition. Clin Gastroenterol Hepatol 10:1220-1224
96. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EMM, Sartor RB, Sherman PM, Mayer EA (2013) An update on the use and investigation of probiotics in health and disease. Gut 62:787-796